(Adds share movement in paragraph 2 and details in paragraph 3 onwards) Oct 29 (Reuters) – Intellia Therapeutics said on Wednesday that the U.S. Food and Drug Administration has placed a clinical hold on its two late-stage trials testing an experimental gene-editing therapy for a rare disease that can damage the heart and nerves. Shares of the company fell about 14% in extended trading. Earlier this week, the company said that in one of its gene-editing trials a patient who received the therapy, called nexiguran ziclumeran (nex-z), developed a serious liver injury, prompting a temporary pause in dosing and patient screening. The FDA verbally informed the company of the decision on October 29 and said it would issue a formal letter within 30 days. (Reporting by Kamal Choudhury in Bengaluru; Editing by Alan Barona)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
